Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

433 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Asian Pacific Association for the Study of the Liver consensus statements on the diagnosis, management and treatment of hepatitis C virus infection.
Asian Pacific Association for the Study of the Liver (APASL) Hepatitis C Working Party; McCaughan GW, Omata M, Amarapurkar D, Bowden S, Chow WC, Chutaputti A, Dore G, Gane E, Guan R, Hamid SS, Hardikar W, Hui CK, Jafri W, Jia JD, Lai MY, Wei L, Leung N, Piratvisuth T, Sarin S, Sollano J, Tateishi R. Asian Pacific Association for the Study of the Liver (APASL) Hepatitis C Working Party, et al. Among authors: gane e. J Gastroenterol Hepatol. 2007 May;22(5):615-33. doi: 10.1111/j.1440-1746.2007.04883.x. J Gastroenterol Hepatol. 2007. PMID: 17444847 No abstract available.
Shorter durations and lower doses of peginterferon alfa-2a are associated with inferior hepatitis B e antigen seroconversion rates in hepatitis B virus genotypes B or C.
Liaw YF, Jia JD, Chan HL, Han KH, Tanwandee T, Chuang WL, Tan DM, Chen XY, Gane E, Piratvisuth T, Chen L, Xie Q, Sung JJ, Wat C, Bernaards C, Cui Y, Marcellin P. Liaw YF, et al. Among authors: gane e. Hepatology. 2011 Nov;54(5):1591-9. doi: 10.1002/hep.24555. Hepatology. 2011. PMID: 22045673 Clinical Trial.
VX-222, a non-nucleoside NS5B polymerase inhibitor, in telaprevir-based regimens for genotype 1 hepatitis C virus infection.
Di Bisceglie AM, Sulkowski M, Gane E, Jacobson IM, Nelson D, DeSouza C, Alves K, George S, Kieffer T, Zhang EZ, Kauffman R, Asmal M, Koziel MJ. Di Bisceglie AM, et al. Among authors: gane e. Eur J Gastroenterol Hepatol. 2014 Jul;26(7):761-73. doi: 10.1097/MEG.0000000000000084. Eur J Gastroenterol Hepatol. 2014. PMID: 24901821 Clinical Trial.
Concordance of sustained virological response 4, 12, and 24 weeks post-treatment with sofosbuvir-containing regimens for hepatitis C virus.
Yoshida EM, Sulkowski MS, Gane EJ, Herring RW Jr, Ratziu V, Ding X, Wang J, Chuang SM, Ma J, McNally J, Stamm LM, Brainard DM, Symonds WT, McHutchison JG, Beavers KL, Jacobson IM, Reddy KR, Lawitz E. Yoshida EM, et al. Among authors: gane ej. Hepatology. 2015 Jan;61(1):41-5. doi: 10.1002/hep.27366. Epub 2014 Nov 24. Hepatology. 2015. PMID: 25314116 Clinical Trial.
Twenty-eight day safety, antiviral activity, and pharmacokinetics of tenofovir alafenamide for treatment of chronic hepatitis B infection.
Agarwal K, Fung SK, Nguyen TT, Cheng W, Sicard E, Ryder SD, Flaherty JF, Lawson E, Zhao S, Subramanian GM, McHutchison JG, Gane EJ, Foster GR. Agarwal K, et al. Among authors: gane ej. J Hepatol. 2015 Mar;62(3):533-40. doi: 10.1016/j.jhep.2014.10.035. Epub 2014 Oct 30. J Hepatol. 2015. PMID: 25450717 Clinical Trial.
433 results